Ovarian cancer: Genomic analysis

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Wei, W ^a   Dizon, D ^b   Vathipadiekal, V ^a   Birrer, M J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Clinical trials; Genomics; Ovarian

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC REGULATION; GENOMIC INSTABILITY; HUMAN; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION;

CANCER; CLINICAL TRIALS; GENOMICS; OVARIAN;

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888213232     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt462     Document Type: Article

References (75)

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. Chornokur G, Amankwah EK, Schildkraut JM et al. Global ovarian cancer health disparities. Gynecol Oncol 2013; 129: 258-264.
3. Colombo N, Peiretti M, Castiglione M. Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4):24-26.
4. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol 2012; 125: 271-277.
5. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
6. Galaal K, Naik R, Bristow RE et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2010; CD007822.
7. Chang SJ, Hodeib M, Chang J et al. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013; 130: 493-498.
8. Borley J, Wilhelm-Benartzi C, Brown R et al. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer 2012; 107: 1069-1074.
9. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
10. Darcy KM, Brady WE, McBroom JW et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. Gynecol Oncol 2008; 111: 487-495.
11. Farley J, Fuchiuji S, Darcy KM et al. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimallyresected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol 2009; 113: 341-347.
12. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001; 38: 87-95.
13. Malpica A. Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 2008; 27: 175-181.
14. Bodurka DC, Deavers MT, Tian C et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 2012; 118: 3087-3094.
15. Fukumoto M, Nakayama K. Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma? Pathol Int 2006; 56: 233-239.
16. Lachance JA, Shutter J, Atkins KA et al. Utilization of a uniform grading system for interpreting serous ovarian cancer. Am J Obstet Gynecol 2008; 199: 189. e1-189.e6.
17. Bonome T, Lee JY, Park DC et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65: 10602-10612.
18. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 2006; 94: 904-913.
19. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-4729.
20. Shedden KA, Kshirsagar MP, Schwartz DR et al. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005; 11: 2123-2131.
21. Stany MP, Vathipadiekal V, Ozbun L et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 2011; 6: e21121-
22. Wamunyokoli FW, Bonome T, Lee JY et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 2006; 12: 690-700.
23. Wu R, Hendrix-Lucas N, Kuick R et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3 K/Pten signaling pathways. Cancer Cell 2007; 11: 321-333.
24. Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005; 11: 6422-6430.
25. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
26. Enomoto T, Weghorst CM, Inoue M et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991; 139: 777-785.
27. Gemignani ML, Schlaerth AC, Bogomolniy F et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378-381.
28. Singer G, Oldt R, III, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486.
29. Wright K, Wilson P, Morland S et al. beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 1999; 82: 625-629.
30. Obata K, Morland SJ, Watson RH et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2095-2097.
31. Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174: 1597-1601.
32. Campbell IG, Russell SE, Choong DY et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-7681.
33. Anglesio MS, Carey MS, Kobel M et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011; 121: 407-415.
34. Jones S, Wang TL, Shih I et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
35. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
36. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-1668.
37. Anglesio MS, George J, Kulbe H et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011; 17: 2538-2548.
38. Mandai M, Matsumura N, Baba T et al. Ovarian clear cell carcinoma as a stressresponsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett 2011; 310: 129-133.
39. Le TC, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 2007; 3: 341-348.
40. Rauh-Hain JA, Penson RT. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2008; 18: 934-936.
41. Miyazawa M, Yasuda M, Fujita M et al. Therapeutic strategy targeting the mTORHIF- 1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 2009; 59: 19-27.
42. Takano M, Kikuchi Y, Kudoh K et al. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Int J Clin Oncol 2011; 16: 605-609.
43. Daz-Padilla I, Malpica AL, Minig L et al. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012; 126: 279-285.
44. Gershenson DM, Sun CC, Lu KH et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006; 108: 361-368.
45. Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24: 1053-1065.
46. May T, Virtanen C, Sharma M et al. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol 2010; 117: 9-17.
47. Anglesio MS, Arnold JM, George J et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008; 6: 1678-1690.
48. Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
49. Farley J, Brady WE, Vathipadiekal V et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, singlearm, phase 2 study. Lancet Oncol 2013; 14: 134-140.
50. Schmeler KM, Sun CC, Bodurka DC et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008; 108: 510-514.
51. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012; 17: 956-962.
52. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
53. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.
54. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011; 13: 442-449.
55. Liu JF, Tolaney SM, Birrer M et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013.
56. Lancaster JM, Dressman HK, Whitaker RS et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004; 11: 51-59.
57. Berchuck A, Iversen ES, Lancaster JM et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005; 11: 3686-3696.
58. Mok SC, Bonome T, Vathipadiekal V et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009; 16: 521-532.
59. Gibson MA, Leavesley DI, Ashman LK. Microfibril-associated glycoprotein-2 specifically interacts with a range of bovine and human cell types via alphaVbeta3 integrin. J Biol Chem 1999; 274: 13060-13065.
60. Ellis PD, Metcalfe JC, Hyvonen M et al. Adhesion of endothelial cells to NOV is mediated by the integrins alphavbeta3 and alpha5beta1. J Vasc Res 2003; 40: 234-243.
61. Hall M, Gourley C, McNeish I et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013; 108: 250-258.
62. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
63. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
64. Birrer MJ, Johnson ME, Hao K et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25: 2281-2287.
65. Wei et al. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 2013; 123(10): 4435-4448.
66. Spentzos D, Levine DA, Ramoni MF et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700-4710.
67. Robinson-Smith TM, Isaacsohn I, Mercer CA et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 2007; 67: 5708-5716.
68. Thompson MS, Mok SC. Immunopathogenesis of ovarian cancer. Minerva Med 2009; 100: 357-370.
69. Engler DA, Gupta S, Growdon WB et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One 2012; 7: e30996.
70. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129.
71. Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 2011; 17: 283-292.
72. Harding TC, Long L, Palencia S et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013; 5: 178ra39.
73. Ledermann JA, Hackshaw A, Kaye S et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29: 3798-3804.
74. Zhang H, Lorianne M, Baker K et al. FP-1039 (FGFR1:Fc), a soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. In: NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. (Abst B55). 22-26 October, San Francisco, CA, 2007.
75. Harding T, Palencia S, Long L et al. Preclinical efficacy of FP-1039 (FGFR1:Fc) in endometrial carcinoma models with activating mutations in FGFR2. In: American Association for Cancer Research (AACR) 101st Annual Meeting 2010. 17-21 April 2010, Washington, DC.